Fahar Merchant
Chief Executive Officer at MEDICENNA THERAPEUTICS CORP.
Net worth: 7 M $ as of 30/03/2024
Fahar Merchant active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Chief Executive Officer | 01/02/2015 | - |
| Chairman | 01/02/2015 | - | |
| Founder | 01/02/2015 | - | |
| President | 01/02/2015 | - | |
Medicenna Therapeutics, Inc.
 Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Chief Executive Officer | 30/09/2012 | - |
| Chairman | 30/09/2012 | - | |
| Founder | 30/09/2012 | - | |
| President | 30/09/2012 | - |
Career history of Fahar Merchant
Former positions of Fahar Merchant
| Companies | Position | Start | End |
|---|---|---|---|
| SOPHIRIS BIO | Chief Executive Officer | 17/04/2005 | 17/04/2011 |
| President | 17/04/2005 | 17/04/2011 | |
| Aries Biologics, Inc. | President | 31/03/2002 | 31/03/2005 |
| KS Biomedix Plc | Director/Board Member | 31/12/2002 | 31/12/2002 |
| Chief Tech/Sci/R&D Officer | 31/05/2001 | 31/12/2002 | |
| KS Avicenna, Inc. | President | 31/05/2001 | 31/05/2002 |
Avicenna Medica, Inc.
 Avicenna Medica, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Xenova KS Ltd., Avicenna Medica, Inc. develops and provides cytotoxic agent delivery products. The Canadian company was founded by Fahar Merchant. Avicenna Medica was acquired by K.S. Biomedix Holdings Plc on July 13, 2001 for $58.72 million. | Founder | 31/12/1999 | 30/06/2001 |
| Intelligene Expressions, Inc. | Founder | 31/12/1991 | 30/06/2001 |
Training of Fahar Merchant
| University of Western Ontario | Doctorate Degree |
| University of Birmingham | Undergraduate Degree |
Statistics
International
| Canada | 7 |
| United Kingdom | 3 |
| United States | 2 |
Operational
| President | 5 |
| Founder | 4 |
| Chief Executive Officer | 3 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Electronic Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 8 |
|---|---|
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
Avicenna Medica, Inc.
Avicenna Medica, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Xenova KS Ltd., Avicenna Medica, Inc. develops and provides cytotoxic agent delivery products. The Canadian company was founded by Fahar Merchant. Avicenna Medica was acquired by K.S. Biomedix Holdings Plc on July 13, 2001 for $58.72 million. | Electronic Technology |
| KS Biomedix Plc | |
| Aries Biologics, Inc. | |
| KS Avicenna, Inc. | |
| Intelligene Expressions, Inc. | |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Health Technology |
| Medicenna Therapeutics Corp. |
- Stock Market
- Insiders
- Fahar Merchant
- Experience
